218 related articles for article (PubMed ID: 32949229)
1. Associations of sleep characteristics with alpha-synuclein in cerebrospinal fluid in older adults.
Wang XT; Liu FT; Bi YL; Shen XN; Xu W; Wang J; Tan L; Yu JT
Ann Clin Transl Neurol; 2020 Oct; 7(10):2026-2034. PubMed ID: 32949229
[TBL] [Abstract][Full Text] [Related]
2. α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies.
van Steenoven I; Majbour NK; Vaikath NN; Berendse HW; van der Flier WM; van de Berg WDJ; Teunissen CE; Lemstra AW; El-Agnaf OMA
Mov Disord; 2018 Nov; 33(11):1724-1733. PubMed ID: 30440090
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.
Katayama T; Sawada J; Kikuchi-Takeguchi S; Kano K; Takahashi K; Saito T; Okizaki A; Hasebe N
Neurosci Lett; 2020 Jan; 715():134564. PubMed ID: 31733322
[TBL] [Abstract][Full Text] [Related]
4. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
[TBL] [Abstract][Full Text] [Related]
5. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
[TBL] [Abstract][Full Text] [Related]
6. Increased CSF α-synuclein levels in Alzheimer's disease: correlation with tau levels.
Slaets S; Vanmechelen E; Le Bastard N; Decraemer H; Vandijck M; Martin JJ; De Deyn PP; Engelborghs S
Alzheimers Dement; 2014 Oct; 10(5 Suppl):S290-8. PubMed ID: 24439167
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid α-synuclein and Lewy body-like symptoms in normal controls, mild cognitive impairment, and Alzheimer's disease.
Mackin RS; Insel P; Zhang J; Mohlenhoff B; Galasko D; Weiner M; Mattsson N
J Alzheimers Dis; 2015; 43(3):1007-16. PubMed ID: 25125463
[TBL] [Abstract][Full Text] [Related]
8. Investigating alpha-synuclein co-pathology in Alzheimer's disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay.
Bellomo G; Toja A; Paolini Paoletti F; Ma Y; Farris CM; Gaetani L; Salvadori N; Chiasserini D; Wojdaƚa AL; Concha-Marambio L; Parnetti L
Alzheimers Dement; 2024 Apr; 20(4):2444-2452. PubMed ID: 38323747
[TBL] [Abstract][Full Text] [Related]
9. Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease.
Kasuga K; Tokutake T; Ishikawa A; Uchiyama T; Tokuda T; Onodera O; Nishizawa M; Ikeuchi T
J Neurol Neurosurg Psychiatry; 2010 Jun; 81(6):608-10. PubMed ID: 20522869
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease.
Hall S; Surova Y; Öhrfelt A; ; Blennow K; Zetterberg H; Hansson O
Mov Disord; 2016 Jun; 31(6):898-905. PubMed ID: 26878815
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal Fluid Alpha-Synuclein Improves the Differentiation between Dementia with Lewy Bodies and Alzheimer's Disease in Clinical Practice.
Lilamand M; Clery J; Vrillon A; Mouton-Liger F; Cognat E; Gaubert S; Hourregue C; Martinet M; Dumurgier J; Hugon J; Bouaziz-Amar E; Paquet C
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362275
[TBL] [Abstract][Full Text] [Related]
12. The value of cerebrospinal fluid α-synuclein and the tau/α-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology.
Førland MG; Tysnes OB; Aarsland D; Maple-Grødem J; Pedersen KF; Alves G; Lange J
Eur J Neurol; 2020 Jan; 27(1):43-50. PubMed ID: 31293044
[TBL] [Abstract][Full Text] [Related]
13. Sleep characteristics and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact older adults: The CABLE study.
Xu W; Tan L; Su BJ; Yu H; Bi YL; Yue XF; Dong Q; Yu JT
Alzheimers Dement; 2020 Aug; 16(8):1146-1152. PubMed ID: 32657026
[TBL] [Abstract][Full Text] [Related]
14. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.
Skogseth RE; Bronnick K; Pereira JB; Mollenhauer B; Weintraub D; Fladby T; Aarsland D
J Parkinsons Dis; 2015; 5(4):783-92. PubMed ID: 26599300
[TBL] [Abstract][Full Text] [Related]
15. Dementia with lewy bodies: GBA1 mutations are associated with cerebrospinal fluid alpha-synuclein profile.
Lerche S; Machetanz G; Wurster I; Roeben B; Zimmermann M; Pilotto A; Preische O; Stransky E; Deuschle C; Hauser AK; Schulte C; Lachmann I; Waniek K; Gasser T; Berg D; Maetzler W; Brockmann K
Mov Disord; 2019 Jul; 34(7):1069-1073. PubMed ID: 31189032
[TBL] [Abstract][Full Text] [Related]
16. Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study.
Delgado-Alvarado M; Gago B; Gorostidi A; Jiménez-Urbieta H; Dacosta-Aguayo R; Navalpotro-Gómez I; Ruiz-Martínez J; Bergareche A; Martí-Massó JF; Martínez-Lage P; Izagirre A; Rodríguez-Oroz MC
Mov Disord; 2017 Jul; 32(7):1066-1073. PubMed ID: 28548309
[TBL] [Abstract][Full Text] [Related]
17. CSF α-synuclein concentrations do not fluctuate over hours and are not correlated to amyloid β in humans.
Spies PE; Slats D; Rikkert MG; Tseng J; Claassen JA; Verbeek MM
Neurosci Lett; 2011 Oct; 504(3):336-8. PubMed ID: 22001363
[TBL] [Abstract][Full Text] [Related]
18. A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid.
Kruse N; Schlossmacher MG; Schulz-Schaeffer WJ; Vanmechelen E; Vanderstichele H; El-Agnaf OM; Mollenhauer B
PLoS One; 2016; 11(4):e0153564. PubMed ID: 27116005
[TBL] [Abstract][Full Text] [Related]
19. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.
Mollenhauer B; Parnetti L; Rektorova I; Kramberger MG; Pikkarainen M; Schulz-Schaeffer WJ; Aarsland D; Svenningsson P; Farotti L; Verbeek MM; Schlossmacher MG
J Neurochem; 2016 Oct; 139 Suppl 1():290-317. PubMed ID: 26452984
[TBL] [Abstract][Full Text] [Related]
20. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y
J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
